2/120
0.1 / 5 stars
All 120 Win/Lose results shown below
AARD Roast Me summary
Aardvark Therapeutics, Inc. (AARD). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinAARD / S&P 52.79% / 15.20% |
LoseAARD / S&P AARD unavailable / 15.00% |
LoseAARD / S&P AARD unavailable / 50.40% |
| 2026-Q10/3 |
LoseAARD / S&P -71.28% / -4.33% |
LoseAARD / S&P AARD unavailable / 11.30% |
LoseAARD / S&P AARD unavailable / 27.70% |
| 2025-Q40/3 |
LoseAARD / S&P -1.24% / 2.65% |
LoseAARD / S&P AARD unavailable / 9.00% |
LoseAARD / S&P AARD unavailable / 13.40% |
| 2025-Q30/3 |
LoseAARD / S&P -1.70% / 8.12% |
LoseAARD / S&P AARD unavailable / 4.61% |
LoseAARD / S&P AARD unavailable / 13.45% |
| 2025-Q21/3 |
WinAARD / S&P 80.03% / 10.94% |
LoseAARD / S&P AARD unavailable / 4.83% |
LoseAARD / S&P AARD unavailable / 10.63% |
| 2025-Q10/3 |
LoseAARD / S&P AARD unavailable / -4.27% |
LoseAARD / S&P AARD unavailable / 4.98% |
LoseAARD / S&P AARD unavailable / 10.57% |
| 2024-Q40/3 |
LoseAARD / S&P AARD unavailable / 2.41% |
LoseAARD / S&P AARD unavailable / 5.25% |
LoseAARD / S&P AARD unavailable / 6.15% |
| 2024-Q30/3 |
LoseAARD / S&P AARD unavailable / 5.89% |
LoseAARD / S&P AARD unavailable / 5.89% |
LoseAARD / S&P AARD unavailable / 6.11% |
| 2024-Q20/3 |
LoseAARD / S&P AARD unavailable / 4.28% |
LoseAARD / S&P AARD unavailable / 5.38% |
LoseAARD / S&P AARD unavailable / 5.12% |
| 2024-Q10/3 |
LoseAARD / S&P AARD unavailable / 10.56% |
LoseAARD / S&P AARD unavailable / 5.71% |
LoseAARD / S&P AARD unavailable / 5.59% |
| 2023-Q40/3 |
LoseAARD / S&P AARD unavailable / 11.69% |
LoseAARD / S&P AARD unavailable / 6.81% |
LoseAARD / S&P AARD unavailable / 7.78% |
| 2023-Q30/3 |
LoseAARD / S&P AARD unavailable / -3.27% |
LoseAARD / S&P AARD unavailable / 7.52% |
LoseAARD / S&P AARD unavailable / -5.03% |
| 2023-Q20/3 |
LoseAARD / S&P AARD unavailable / 8.74% |
LoseAARD / S&P AARD unavailable / 9.50% |
LoseAARD / S&P AARD unavailable / -8.57% |
| 2023-Q10/3 |
LoseAARD / S&P AARD unavailable / 7.50% |
LoseAARD / S&P AARD unavailable / 10.77% |
LoseAARD / S&P AARD unavailable / -15.69% |
| 2022-Q40/3 |
LoseAARD / S&P AARD unavailable / 7.56% |
LoseAARD / S&P AARD unavailable / 11.88% |
LoseAARD / S&P AARD unavailable / -17.99% |
| 2022-Q30/3 |
LoseAARD / S&P AARD unavailable / -4.88% |
LoseAARD / S&P AARD unavailable / 13.47% |
LoseAARD / S&P AARD unavailable / -1.41% |
| 2022-Q20/3 |
LoseAARD / S&P AARD unavailable / -16.10% |
LoseAARD / S&P AARD unavailable / 13.71% |
LoseAARD / S&P AARD unavailable / 11.04% |
| 2022-Q10/3 |
LoseAARD / S&P AARD unavailable / -4.60% |
LoseAARD / S&P AARD unavailable / 15.97% |
LoseAARD / S&P AARD unavailable / 42.23% |
| 2021-Q40/3 |
LoseAARD / S&P AARD unavailable / 11.03% |
LoseAARD / S&P AARD unavailable / 15.00% |
LoseAARD / S&P AARD unavailable / 96.40% |
| 2021-Q30/3 |
LoseAARD / S&P AARD unavailable / 0.58% |
LoseAARD / S&P AARD unavailable / 10.77% |
LoseAARD / S&P AARD unavailable / 69.42% |
| 2021-Q20/3 |
LoseAARD / S&P AARD unavailable / 8.55% |
LoseAARD / S&P AARD unavailable / 6.58% |
LoseAARD / S&P AARD unavailable / 51.81% |
| 2021-Q10/3 |
LoseAARD / S&P AARD unavailable / 6.17% |
LoseAARD / S&P AARD unavailable / -1.06% |
LoseAARD / S&P AARD unavailable / 7.39% |
| 2020-Q40/3 |
LoseAARD / S&P AARD unavailable / 12.15% |
LoseAARD / S&P AARD unavailable / -3.72% |
LoseAARD / S&P AARD unavailable / -33.42% |
| 2020-Q30/3 |
LoseAARD / S&P AARD unavailable / 8.93% |
LoseAARD / S&P AARD unavailable / -2.04% |
LoseAARD / S&P AARD unavailable / -27.10% |
| 2020-Q20/3 |
LoseAARD / S&P AARD unavailable / 20.54% |
LoseAARD / S&P AARD unavailable / -0.46% |
LoseAARD / S&P AARD unavailable / -27.11% |
| 2020-Q10/3 |
LoseAARD / S&P AARD unavailable / -19.60% |
LoseAARD / S&P AARD unavailable / 3.47% |
LoseAARD / S&P AARD unavailable / -14.75% |
| 2019-Q40/3 |
LoseAARD / S&P AARD unavailable / 9.07% |
LoseAARD / S&P AARD unavailable / 5.36% |
LoseAARD / S&P AARD unavailable / 2.99% |
| 2019-Q30/3 |
LoseAARD / S&P AARD unavailable / 1.70% |
LoseAARD / S&P AARD unavailable / 5.02% |
LoseAARD / S&P AARD unavailable / 0.21% |
| 2019-Q20/3 |
LoseAARD / S&P AARD unavailable / 4.30% |
LoseAARD / S&P AARD unavailable / 6.64% |
LoseAARD / S&P AARD unavailable / 8.65% |
| 2019-Q10/3 |
LoseAARD / S&P AARD unavailable / 13.65% |
LoseAARD / S&P AARD unavailable / 8.12% |
LoseAARD / S&P AARD unavailable / 14.29% |
| 2018-Q40/3 |
LoseAARD / S&P AARD unavailable / -13.52% |
LoseAARD / S&P AARD unavailable / 9.05% |
LoseAARD / S&P AARD unavailable / 18.23% |
| 2018-Q30/3 |
LoseAARD / S&P AARD unavailable / 7.71% |
LoseAARD / S&P AARD unavailable / 10.21% |
LoseAARD / S&P AARD unavailable / 19.06% |
| 2018-Q20/3 |
LoseAARD / S&P AARD unavailable / 3.43% |
LoseAARD / S&P AARD unavailable / 9.03% |
LoseAARD / S&P AARD unavailable / 14.46% |
| 2018-Q10/3 |
LoseAARD / S&P AARD unavailable / -0.76% |
LoseAARD / S&P AARD unavailable / 7.68% |
LoseAARD / S&P AARD unavailable / 12.46% |
| 2017-Q40/3 |
LoseAARD / S&P AARD unavailable / 6.64% |
LoseAARD / S&P AARD unavailable / 7.03% |
LoseAARD / S&P AARD unavailable / 13.82% |
| 2017-Q30/3 |
LoseAARD / S&P AARD unavailable / 4.48% |
LoseAARD / S&P AARD unavailable / 5.68% |
LoseAARD / S&P AARD unavailable / 17.57% |
| 2017-Q20/3 |
LoseAARD / S&P AARD unavailable / 3.09% |
LoseAARD / S&P AARD unavailable / 4.83% |
LoseAARD / S&P AARD unavailable / 17.74% |
| 2017-Q10/3 |
LoseAARD / S&P AARD unavailable / 6.07% |
LoseAARD / S&P AARD unavailable / 3.67% |
LoseAARD / S&P AARD unavailable / 13.32% |
| 2016-Q40/3 |
LoseAARD / S&P AARD unavailable / 3.82% |
LoseAARD / S&P AARD unavailable / 2.09% |
LoseAARD / S&P AARD unavailable / 7.05% |
| 2016-Q30/3 |
LoseAARD / S&P AARD unavailable / 3.85% |
LoseAARD / S&P AARD unavailable / 0.20% |
LoseAARD / S&P AARD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | AARD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -31.52% | 20.78% |
| Annualized return | -31.52% | 20.78% |
5Y · 2025-02-13 to 2026-08-28
| Metric | AARD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -60.28% | 83.14% |
| Annualized return | -16.86% | 12.86% |
10Y · 2025-02-13 to 2026-08-28
| Metric | AARD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -60.28% | 319.30% |
| Annualized return | -8.82% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |